Theodore R. Schroeder

Theodore R. Schroeder, listed as chief executive, has filed trades across 3 companies (mainly through SEC (Form 4)), most often in Nabriva Therapeutics plc, Collegium Pharmaceutical, Inc and Phathom Pharmaceuticals, Inc. In total, 72 filings cover trades dated from 24 May 2018 to 16 April 2025.

On the market, this insider has only ever bought: 3 purchases, €179k in total. A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant. The rest of the record consists of 69 share grants.

The median purchase comes to €51k. On 2 out of 3 purchases, another insider of the same company was buying within the same 30 days. When several insiders buy within a few weeks of each other, analysts speak of a cluster purchase.

The latest filing, published on 16 April 2025, reports a share grant in Phathom Pharmaceuticals, Inc. The most recent open-market purchase was published on 29 December 2021, 1,760 days ago. Filings reach the SEC (Form 4) feed a median of 2 days after the trade. The legal deadline for a Form 4 is two business days after the transaction. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.